Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the significant progress in PCa systemic therapy,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/2/173 |
| _version_ | 1797416018355683328 |
|---|---|
| author | Maria Adamaki Vassilios Zoumpourlis |
| author_facet | Maria Adamaki Vassilios Zoumpourlis |
| author_sort | Maria Adamaki |
| collection | DOAJ |
| description | Prostate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the significant progress in PCa systemic therapy, therapeutic response is usually transient, and invasive disease is associated with high mortality rates. Immunotherapy has emerged as an efficacious and non-toxic treatment alternative that perfectly fits the rationale of precision medicine, as it aims to treat patients on the basis of patient-specific, immune-targeted molecular traits, so as to achieve the maximum clinical benefit. Antibodies acting as immune checkpoint inhibitors and vaccines entailing tumor-specific antigens seem to be the most promising immunotherapeutic strategies in offering a significant survival advantage. Even though patients with localized disease and favorable prognostic characteristics seem to be the ones that markedly benefit from such interventions, there is substantial evidence to suggest that the survival benefit may also be extended to patients with more advanced disease. The identification of biomarkers that can be immunologically targeted in patients with disease progression is potentially amenable in this process and in achieving significant advances in the decision for precision treatment of PCa. |
| first_indexed | 2024-03-09T05:57:47Z |
| format | Article |
| id | doaj.art-ef324908d156498e8475ae3d6d46f6e8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:57:47Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ef324908d156498e8475ae3d6d46f6e82023-12-03T12:12:26ZengMDPI AGCancers2072-66942021-01-0113217310.3390/cancers13020173Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate CancerMaria Adamaki0Vassilios Zoumpourlis1Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 48 Vassileos Constantinou Avenue, 11635 Athens, GreeceBiomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 48 Vassileos Constantinou Avenue, 11635 Athens, GreeceProstate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the significant progress in PCa systemic therapy, therapeutic response is usually transient, and invasive disease is associated with high mortality rates. Immunotherapy has emerged as an efficacious and non-toxic treatment alternative that perfectly fits the rationale of precision medicine, as it aims to treat patients on the basis of patient-specific, immune-targeted molecular traits, so as to achieve the maximum clinical benefit. Antibodies acting as immune checkpoint inhibitors and vaccines entailing tumor-specific antigens seem to be the most promising immunotherapeutic strategies in offering a significant survival advantage. Even though patients with localized disease and favorable prognostic characteristics seem to be the ones that markedly benefit from such interventions, there is substantial evidence to suggest that the survival benefit may also be extended to patients with more advanced disease. The identification of biomarkers that can be immunologically targeted in patients with disease progression is potentially amenable in this process and in achieving significant advances in the decision for precision treatment of PCa.https://www.mdpi.com/2072-6694/13/2/173prostate cancerimmunotherapyprecision medicinepredictive biomarkersimmune checkpoint inhibitors |
| spellingShingle | Maria Adamaki Vassilios Zoumpourlis Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer Cancers prostate cancer immunotherapy precision medicine predictive biomarkers immune checkpoint inhibitors |
| title | Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer |
| title_full | Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer |
| title_fullStr | Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer |
| title_full_unstemmed | Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer |
| title_short | Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer |
| title_sort | immunotherapy as a precision medicine tool for the treatment of prostate cancer |
| topic | prostate cancer immunotherapy precision medicine predictive biomarkers immune checkpoint inhibitors |
| url | https://www.mdpi.com/2072-6694/13/2/173 |
| work_keys_str_mv | AT mariaadamaki immunotherapyasaprecisionmedicinetoolforthetreatmentofprostatecancer AT vassilioszoumpourlis immunotherapyasaprecisionmedicinetoolforthetreatmentofprostatecancer |